Form 4: Dexcom Executive Michael Jon Brown Sells Shares Under 10b5-1 Plan

Michael Jon Brown, EVP and Chief Legal Officer of Dexcom Inc., sold shares of Dexcom stock on March 28, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 28, 2024, Michael Jon Brown, the EVP and Chief Legal Officer of Dexcom Inc., sold 2,524 shares of common stock at a weighted average price of $140.0156 and 100 shares at $140.73.
• The sales were executed under a 10b5-1 trading plan adopted on December 15, 2022, and amended on August 29, 2023.
• Following the transactions, Brown beneficially owns 68,682 shares of Dexcom, including 60,303 unvested restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales by an executive under a pre-arranged plan. It doesn't convey any particularly positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often related to personal financial planning. The use of 10b5-1 plans allows insiders to sell shares over a period of time while avoiding concerns about insider trading.

Comparison to Industry Standards

• Executive compensation and stock ownership are typical for executives in publicly traded companies like Dexcom.
• 10b5-1 trading plans are a standard practice among corporate executives to diversify their holdings and manage personal finances, similar to practices at companies like Medtronic or Abbott.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the use of a 10b5-1 plan suggests it's part of a pre-determined strategy and not necessarily indicative of the executive's view on the company's future prospects.

Key Dates